DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
当前地点:
>
>
> This Story

Forward Printable StoryPrint Comment

 

 

Molecular Imaging Homepage

New method enables accurate diagnosis of Alzheimer's disease

MILabs’ VECTor6 with groundbreaking PET performance named Innovation of the Year at the WMIC 2018

Ontario women to get PET scans to help plan treatment in locally advanced cervix cancer

Zecotek ships over $225,000 of LFS scintillation crystals

Results published for Blue Earth Diagnostics' LOCATE trial for 18F Fluciclovine PET/CT imaging

MILabs Broadband Photon Tomography nominated for Innovation of the Year at WMIC 2018

Lilly announces positive phase 3 results in study of Flortaucipir PET imaging agent

Aspect Imaging and Brightonix Imaging will be showcasing the SimPET simultaneous preclinical PET/MR insert at WMIC 2018

XingImaging announces Alzheimer's Disease PET imaging in Mainland China

ImaginAb and CPDC announce clinical trial supply manufacture and distribution agreement for ImaginAb’s CD8 Immuno PET Tracer

New targeted radiation therapy increases survival for neuroendocrine tumors

Press releases may be edited for formatting or style
The University of Kansas Cancer Center is one of the first in the region to offer patients Lutathera®, approved by the FDA earlier this year. Lutathera provides advanced, targeted nuclear medicine radiation therapy to cancer patients with primary neuroendocrine tumors of the small bowel and pancreas. This life-threatening cancer can metastasize to organs such as the liver.

Until now, octreotide therapy to slow or stop tumor growth was the standard of care. Octreotide is a more effective synthetic version of somatostatin, a growth inhibiting hormone occurring naturally in the body.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



"Combining octreotide with Lutathera increases patients' median, progression-free 20-month survival to 65% versus 10% for octreotide alone," says Wendell Yap, MD, nuclear medicine specialist at The University of Kansas Health System.

Patients receive Lutathera intravenously with an amino acid that protects their kidneys from radiation. The process takes 4-6 hours. After their infusion, Lutathera patients don't need to avoid human contact. Although they are slightly radioactive, they receive a much lower dose of radiation compared to highly radioactive nuclear medicine therapies such as Iodine 131 or Yttrium 90.

At the cancer center, patients receive four Lutathera infusions, one every two months. Each infusion is followed by an injection of long-acting octreotide to inhibit tumor growth until the next infusion. After the last infusion, a patient may receive octreotide for up to 18 months, depending on whether the cancer grows or metastasizes.

Raed Al-Rajabi, MD, medical oncologist at the cancer center, is optimistic about Lutathera's future. "It could be primary, secondary and tertiary treatment as long as the patient meets the criteria," he says. "It's one of the tools that we can use to take care of this cancer for a very long time."

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

做广告
提升您的品牌知名度
拍卖+私人销售
获得最好的价格
买设备/配件
找到最低价格
每日新闻
阅读最新信息
目录
浏览所有的DOTmed用户
DOTmed上的伦理
查看我们的伦理计划
金子分开供营商节目
接收PH要求
金子服务经销商节目
接收请求
提供保健服务者
查看所有的HCP(简称医疗保健提供商)的工具
工作/训练
查找/申请工作
Parts Hunter +EasyPay
获取配件报价
最近证明
查看最近通过认证的用户
最近额定
查看最近通过认证的用户
出租中央
租用设备优惠
卖设备/配件
得到最划算
服务技术员论坛
查找帮助和建议
简单的征求建议书
获取设备报价
真正商业展览
查找对设备的服务
对这个站点的通入和用途是受期限和条件我们支配 法律公告 & 保密性通知
物产和业主对 DOTmed.com,公司 Copyright ©2001-2018 DOTmed.com, Inc.
版权所有